WHO Expects Bharat Biotech To Provide Clarifications On Covaxin By The Weekend

WHO expects to receive clarifications from Bharat Biotech by the end of this week on its COVID-19 vaccine, Covaxin, and that it will meet on November 3 for a final EUL risk-benefit analysis for the Emergency Use Listing.

Geneva (Ukraine): The World Health Organisation (WHO) tweeted on Wednesday that it expects to receive clarifications from Bharat Biotech by the end of this week on its COVID-19 vaccine, Covaxin, and that it will meet on November 3 for a final EUL risk-benefit analysis for the Emergency Use Listing, according to the WHO.The World Health Organization also tweeted a video of WHO Health Emergency Programme Executive Director Dr Mike Ryan, who said that the WHO is But it's also vital that WHO makes a recommendation like this globally, because we're supposed to be completely certain, and it's really important that we gather all of the pertinent information not only on the vaccine itself but also on the manufacturing processes and everything else, he said, because we're being asked and responded to this invitation and then have to make a recommendation from there, he said.As we looked at every piece of data, weve looked at the entire manufacturing cycle, And it is especially frustrating if you have a particular vaccine that is not readily available in another country and you are unable to travel.That becomes a problem, Ryan said.The advisory group and its members' work was of the highest standard, and it takes some time to accomplish that.

And if it takes another week or two, the dossier will be finished, so that the committee has a chance to look at it and then WHO will make the correct decision and give the right advice to the world.Ryan has said that the Emergency Committee of the International Health Regulations has been very clear, and that using vaccination status as the only way of limiting travel is a double injustice.And that's a double injustice, he said in a video posted by WHO.Dr Mariangela Simao, Assistant Director General of Access to Medicines and Health Products, explained the process of emergency approvals of these vaccines and how it is made possible in this process.She said in the video that it is important to emphasize that no vaccine candidate should be used or issued an emergency license if it hasn't completed phase three trials because it is during phase three trials that you conduct the testing The task isn't done yet, because Simao said that before the country level, you need to test to see if the vaccine was well made and tested under good manufacturing practices and quality control.So, this means that it has gone through a lot of scrutiny by the time it is released.